Decreased activity of lecithin:cholesterol acyltransferase and hepatic lipase in chronic hypothyroid rats: Implications for reverse cholesterol transport

  • Martha Franco
  • Graciela Castro
  • Luis Romero
  • Juan Carlos Regalado
  • Claudia Huesca-Gómez
  • Serafín Ramírez
  • Oscar Peréz-Méndez
  • Aida Medina
  • Carlos Posadas-Romero
  • Luis F. Montaño
Part of the Molecular and Cellular Biochemistry: An International Journal for Chemical Biology in Health and Disease book series (DMCB, volume 41)


Chronic hypothyroidism is frequently associated with atherosclerosis due to increased cholesterol plasma levels; nevertheless, the contribution of impaired reverse cholesterol transport (RCT) in this process has not been completely elucidated. The aim of this study was to evaluate the effect of thyroidectomy (Htx) upon the main stages of RCT in rats. Plasma lipid alterations induced by thyroidectomy showed a slight, but significant, reduction of total plasma triglycerides, a 300% increase of LDLcholesterol and a 25% decrease in HDL-cholesterol compared to control rats. We evaluated the first stage of RCT determining 3H-cholesterol efflux in Fu5AH cells. The capacity of HDL obtained from Htx rats to promote cholesterol efflux was similar to that of controls. Lecithin:cholesterol acyltransferase (LCAT) activity, the second stage and the driving force of RCT was 30% lower in Htx animals compared to controls, as determined by reconstituted HDL used as an external substrate. Lipoproteins are remodeled by hepatic lipase; the mean activity of this enzyme in postheparin plasma of Htx animals was reduced by 30% compared to controls, thus suggesting an impaired HDL remodeling by this enzyme in the hypothyroid status. In contrast, lipoprotein lipase activity in the Htx group was unchanged. In summary, this study demonstrates that chronic hypothyroidism in the rat induced an impaired RCT mainly at the cholesterol esterification, and HDL remodeling mediated by hepatic lipase. The latter probably results in an abnormal HDL structure, i.e. phospholipid enrichment, which contributes to decrease HDLapo AI fractional catabolic rates. (Mol Cell Biochem246:51-56, 2003)

Key words

reverse cholesterol transport cholesterol efflux high-density lipoproteins lecithin:cholesterol acyltranferase hepatic lipase hypothyroidism 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Miller NE: High-density lipoprotein: A major risk factor for coronary atherosclerosis. Baillieres Clin Endocrinol Metab 1: 603–622, 1987PubMedCrossRefGoogle Scholar
  2. 2.
    Parra HJ, Arveiler D, Evans AE, Cambou JP, Amouyel P, Bingham A, McMaster D, Schaffer P, Douste-Blazy P, Luc G: A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb 12: 701–707, 1992PubMedCrossRefGoogle Scholar
  3. 3.
    Fielding CJ, Fielding PE: Molecular physiology of reverse cholesterol transport. J Lipid Res 36: 211–228, 1995PubMedGoogle Scholar
  4. 4.
    Castro GR, Fielding CJ: Early incorporation of cell-derived cholesterol into pre-β-migrating high-density lipoprotein. Biochemistry 27: 25–29, 1988PubMedCrossRefGoogle Scholar
  5. 5.
    Matveev S, Uittenbogaard A, van Der Westhuyzen D, Smart EJ: Caveolin-1 negatively regulates SR-BI mediated selective uptake of high-density lipoprotein-derived cholesteryl ester. Eur J Biochem 268: 5609–5616, 2001PubMedCrossRefGoogle Scholar
  6. 6.
    Jiang X, Francone OL, Bruce C, Milne R, Mar J, Walsh A, Breslow JL, Tall AR: Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest 98: 2373–2380, 1996PubMedCrossRefGoogle Scholar
  7. 7.
    Barrans A, Collet X, Barbaras R, Jaspard B, Manent J, Vieu C, Chap H, Perret B: Hepatic lipase induces the formation of pre-beta I high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion toin vitroincubation with lipases. J Biol Chem 269: 11572–11577, 1994PubMedGoogle Scholar
  8. 8.
    Taylor AH, Wishart P, Lawless DE, Raymond J, Wong NC: Identification of functional positive and negative thyroid hormone-responsive elements in the rat apolipoprotein AI promoter. Biochemistry 35: 8281–8288, 1996PubMedCrossRefGoogle Scholar
  9. 9.
    Apostolopoulos JJ, Marshall JF, Howlett GJ: Triiodothyronine increases rat apolipoprotein A-I synthesis and alters high-density lipoprotein compositionin vivo.Eur J Biochem 194: 147–154, 1990PubMedCrossRefGoogle Scholar
  10. 10.
    Valdemarsson S, Hedner P, Nilsson-Ehle P: Dyslipoproteinaemia in hypothyroidism of pituitary origin: Effects of L-thyroxine substitution on lipoprotein lipase, hepatic lipase, and on plasma lipoproteins. Acta Endocrinol 103: 192–197, 1983PubMedGoogle Scholar
  11. 11.
    Muls E, Rosseneu M, Blaton V, Lesaffre E, Lamberigts G, De Moor P: Serum lipids and apolipoproteins A-I, A-II and B in primary hypothyroidism before and during treatment. Eur J Clin Invest 14: 12–15, 1984PubMedCrossRefGoogle Scholar
  12. 12.
    Scottolini AG, Bhagavan NV, Oshiro TH, Abe SY: Serum high-density lipoprotein cholesterol concentrations in hypo-and hyperthyroidism. Clin Chem 26: 584–587, 1980PubMedGoogle Scholar
  13. 13.
    Danese MD, Ladenson PW, Meinert CL, Powe NR: Clinical review 115: Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: A quantitative review of the literature. J Clin Endocrinol Metab 85: 2993–3001, 2000PubMedCrossRefGoogle Scholar
  14. 14.
    Dullaart RP, Hoogenberg K, Groener JE, Dikkeschei LD, Erkelens DW, Doorenbos H: The activity of cholesteryl ester transfer protein is decreased in hypothyroidism: A possible contribution to alterations in high-density lipoproteins. Eur J Clin Invest 20: 581–587, 1990PubMedCrossRefGoogle Scholar
  15. 15.
    Tan KC, Shiu SW, Kung AW: Effect of thyroid dysfunction on high-density lipoprotein subfraction metabolism: Roles of hepatic lipase and cholesteryl ester transfer protein. J Clin Endocrinol Metab 83: 2921–2924, 1998PubMedCrossRefGoogle Scholar
  16. 16.
    Tall AR: Plasma cholesteryl ester transfer protein and high-density lipoproteins: New insights from molecular genetic studies. J Intern Med 237: 5–12, 1995PubMedCrossRefGoogle Scholar
  17. 17.
    Yamashita S, Maruyama T, Hirano KI, Sakai N, Nakajima N, Matsuzawa Y: Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. Atherosclerosis 152: 271–285, 2000PubMedCrossRefGoogle Scholar
  18. 18.
    Huesca-Gomez C, Franco M, Luc G, Montano LF, Masso F, PosadasaRomero C, Perez-Mendez O: Chronic hypothyroidism induces abnormal structure of high-density lipoproteins and impairs kinetics of apolipoprotein A-I in the rat. Metabolism 51: 443–450, 2002PubMedCrossRefGoogle Scholar
  19. 19.
    Franco M, Tapia E, Martinez F, Davila ME, Grimaldo JI, Medina K, Herrera-Acosta J: Adenosine regulates renal nitric oxide production in hypothyroid rats. J Am Soc Nephrol 10: 1681–1688, 1999PubMedGoogle Scholar
  20. 20.
    Lowry OH, Rosebrough HJ, Farr AL. Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275, 1951PubMedGoogle Scholar
  21. 21.
    de Ia Llera Mora M, Atger V, Paul JL Fournier N, Moatti N, Giral P, Friday KE, Rothblat G: A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum complement, esterification and transfer. Arterioscler Thromb 14: 1056–1065, 1994CrossRefGoogle Scholar
  22. 22.
    Chen C, Albers JJ: Characterization of proteoliposomes containing apoprotein A-I. A new substrate for the measurement of lecithin cholesterol acyltransferase activity. J Lipid Res 23: 680–691, 1882Google Scholar
  23. 23.
    Nilsson-Ehle, Schotz MC: A stable, radioactive substrate emulsion for assay of lipoprotein lipase. J Lipid Res 17: 536–41, 1976PubMedGoogle Scholar
  24. 24.
    Belfrage P, Vaughan M: Simple liquid-liquid partition system for isolation of labeled oleic acid from mixtures with glycerides. J Lipid Res 10: 341–344, 1969PubMedGoogle Scholar
  25. 25.
    Hudig F, Bakker O, Wiersinga WM: Tri-iodothyronine prevents the amiodarone-induced decrease in the expression of the liver low-density lipoprotein receptor gene. J Endocrinol 152:413–421, 1997PubMedCrossRefGoogle Scholar
  26. 26.
    Wiseman SA, Powell JT, Humphries SE, Press M: The magnitude of the hypercholesterolemia of hypothyroidism is associated with variation in the low-density lipoprotein receptor gene. J Clin Endocrinol Metab 77: 108–112, 1993PubMedCrossRefGoogle Scholar
  27. 27.
    Oschry Y, Eisenberg S: Rat plasma lipoproteins: Re-evaluation of a lipoprotein system in an animal devoid of cholesteryl ester transfer activity. J Lipid Res 23: 1099–1106, 1982PubMedGoogle Scholar
  28. 28.
    Jian B, de Ia Llera-Moya M, Ji Y, Wang N, Phillips MC, Swaney JB, Tall AR, Rothblat GH: Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors. J Biol Chem 273: 5599–5606, 1998PubMedCrossRefGoogle Scholar
  29. 29.
    Fournier N, Paul JL, Atger V, Cogny A, Soni T, de la Llera-Moya M, Rothblat G, Moatti N: HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol 17: 2685–2691, 1997PubMedCrossRefGoogle Scholar
  30. 30.
    Carlson LA, Holmquist L: Evidence for the presence in human plasma of Iecithin:cholesterol acyltransferase activity (P-LCAT) specifically esterifying free cholesterol of combined prep-and β-lipoproteins: Studies of fish eye patients and control subjects. Acta Med Scand 218: 197–205, 1985PubMedCrossRefGoogle Scholar
  31. 31.
    Lee M, Kim JQ, Oh H, Park M: Studies on plasma lipid profiles, and LCAT and CETP activities according to hyperlipoproteinemia phenotypes (HLP). Atherosclerosis 159: 381–389, 2001PubMedCrossRefGoogle Scholar
  32. 32.
    Hime NJ, Barter PJ, Rye KA: Evidence that apolipoprotein A-I facilitates hepatic lipase mediating phospholipid hydrolysis in reconstituted HDL containing apolipoprotein AII. Biochemisty 40: 5496–5505, 2001CrossRefGoogle Scholar
  33. 33.
    Pazos F, Alvarez JJ, Rubies-Prat J, Varela C, Lasuncion MA: Longterm thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins. J Clin Endocrinol Metab 80: 652–656, 1995CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • Martha Franco
    • 1
  • Graciela Castro
    • 2
  • Luis Romero
    • 3
  • Juan Carlos Regalado
    • 3
  • Claudia Huesca-Gómez
    • 3
  • Serafín Ramírez
    • 3
  • Oscar Peréz-Méndez
    • 3
  • Aida Medina
    • 4
  • Carlos Posadas-Romero
    • 4
  • Luis F. Montaño
    • 5
  1. 1.Department of NephrologyInstituto Nacional de Cardiología ‘Ignacio Chávez’MéxicoFrance
  2. 2.Institut Pasteur de LilleAtherosclerosis and INSERMLilleFrance
  3. 3.Department of PhysiologyInstituto Nacional de Cardiología ‘Ignacio Chávez’MéxicoFrance
  4. 4.Department of EndocrinologyInstituto Nacional de Cardiología ‘Ignacio Chávez’MéxicoFrance
  5. 5.Department of Cellular BiologyInstituto Nacional de Cardiología ‘Ignacio Chávez’MéxicoFrance

Personalised recommendations